CorMedix to Acquire Substantially All Assets of Heron Therapeutics, Adding Four Hospital Products
CorMedix agrees to buy Heron Therapeutics’ assets, including ZYNRELEF, APONVIE, CINVANTI and SUSTOL, with $145M cash plus stock. Closing expected in Q1 2027.